Literature DB >> 16798675

Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains.

Janelle M Silvers1, Michael Y Aksenov, Marina V Aksenova, Jacob Beckley, Petra Olton, Charles F Mactutus, Rosemarie M Booze.   

Abstract

With the advent of highly active antiretroviral therapy, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is becoming a more chronic, manageable disease; nevertheless, the prevalence of neurological complications of AIDS is increasing. In this study, protein levels of tyrosine hydroxylase (TH) and dopamine transporter (DAT) in the substantia nigra of HIV-infected brains and -seronegative controls were determined by immunoblotting. The immunoreactivity of neuronal specific enolase (NSE) was used to assess cell loss. Although there were no changes in levels of immunoreactive DAT or NSE proteins in HIV brains, levels of immunoreactive TH were significantly reduced, relative to controls. These results suggest that decreases in TH, the rate-limiting enzyme of dopamine synthesis, may be a factor in the neurological manifestations of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16798675      PMCID: PMC3710452          DOI: 10.1080/13550280600724319

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  27 in total

1.  Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues.

Authors:  L Hudson; J Liu; A Nath; M Jones; R Raghavan; O Narayan; D Male; I Everall
Journal:  J Neurovirol       Date:  2000-04       Impact factor: 2.643

Review 2.  Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia.

Authors:  A Nath; C Anderson; M Jones; W Maragos; R Booze; C Mactutus; J Bell; K F Hauser; M Mattson
Journal:  J Psychopharmacol       Date:  2000       Impact factor: 4.153

Review 3.  HIV dementia: the role of the basal ganglia and dopaminergic systems.

Authors:  J R Berger; G Arendt
Journal:  J Psychopharmacol       Date:  2000       Impact factor: 4.153

4.  Quantitative immunochemistry on neuronal loss, reactive gliosis and BBB damage in cortex/striatum and hippocampus/amygdala after systemic kainic acid administration.

Authors:  M Ding; K G Haglid; A Hamberger
Journal:  Neurochem Int       Date:  2000-04       Impact factor: 3.921

5.  Nitration and inactivation of tyrosine hydroxylase by peroxynitrite.

Authors:  B Blanchard-Fillion; J M Souza; T Friel; G C Jiang; K Vrana; V Sharov; L Barrón; C Schöneich; C Quijano; B Alvarez; R Radi; S Przedborski; G S Fernando; J Horwitz; H Ischiropoulos
Journal:  J Biol Chem       Date:  2001-10-05       Impact factor: 5.157

6.  Neuronal damage of the substantia nigra in HIV-1 infected brains.

Authors:  K Itoh; P Mehraein; S Weis
Journal:  Acta Neuropathol       Date:  2000-04       Impact factor: 17.088

7.  The AIDS dementia complex: II. Neuropathology.

Authors:  B A Navia; E S Cho; C K Petito; R W Price
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

8.  Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia.

Authors:  M V Jones; J E Bell; A Nath
Journal:  AIDS       Date:  2000-12-01       Impact factor: 4.177

9.  Nigral degeneration in acquired immune deficiency syndrome (AIDS).

Authors:  M G Reyes; F Faraldi; C S Senseng; C Flowers; R Fariello
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 10.  Molecular basis for interactions of HIV and drugs of abuse.

Authors:  Avi Nath; Kurt F Hauser; Valerie Wojna; Rosemarie M Booze; William Maragos; Mark Prendergast; Wayne Cass; Jadwiga T Turchan
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

View more
  25 in total

1.  Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.

Authors:  Landhing M Moran; Michael Y Aksenov; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

2.  Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage.

Authors:  Shuxian Hu; Wen S Sheng; James R Lokensgard; Phillip K Peterson; R Bryan Rock
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

3.  Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat.

Authors:  Katy M Webb; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

4.  Selective monoaminergic and histaminergic circuit dysregulation following long-term HIV-1 protein exposure.

Authors:  Adam R Denton; Srimal A Samaranayake; Kristin N Kirchner; Robert F Roscoe; Shane N Berger; Steven B Harrod; Charles F Mactutus; Parastoo Hashemi; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

5.  Age-Related Decrease in Tyrosine Hydroxylase Immunoreactivity in the Substantia Nigra and Region-Specific Changes in Microglia Morphology in HIV-1 Tg Rats.

Authors:  David R Goulding; Andrew Kraft; Peter R Mouton; Christopher A McPherson; Valeria Avdoshina; Italo Mocchetti; G Jean Harry
Journal:  Neurotox Res       Date:  2019-07-08       Impact factor: 3.911

6.  Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Mikhail V Pletnikov; Elizabeth L Engle; Patrick M Tarwater; David R Graham; M Christine Zink
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-27       Impact factor: 4.147

Review 7.  Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis.

Authors:  Shuxian Hu; Wen S Sheng; Robert Bryan Rock
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-18       Impact factor: 4.147

8.  Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor.

Authors:  Janelle M Silvers; Marina V Aksenova; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurotoxicology       Date:  2007-07-22       Impact factor: 4.294

Review 9.  Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS.

Authors:  Mark J Ferris; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurosci Biobehav Rev       Date:  2008-03-18       Impact factor: 8.989

10.  Cognitive and motor deficits in older adults with HIV infection: Comparison with normal ageing and Parkinson's disease.

Authors:  Eva M Müller-Oehring; Rosemary Fama; Taylor F Levine; Cheshire Hardcastle; Ryan Goodcase; Talora Martin; Varsha Prabhakar; Helen M Brontë-Stewart; Kathleen L Poston; Edith V Sullivan; Tilman Schulte
Journal:  J Neuropsychol       Date:  2020-10-08       Impact factor: 2.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.